About Avelas

Avelas Biosciences is a biotechnology company focused on developing pegloprastide (also known as AVB-620) with the goal of revolutionizing cancer surgery with real-time margin detection. In a pivotal trial in women with early-stage breast cancer undergoing a lumpectomy, intraoperative imaging of pegloprastide detected up to 75% of the positive margins that resulted from standard-of-care techniques. Beyond breast cancer, pegloprastide has the potential to significantly improve outcomes in a variety of other cancer surgeries.

More about us Watch Video

About Avelas